Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 10/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TYMS | P04818 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Talotrexin SCHEMBL1060263 | 0.99 | DHFR (0.79) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| Talotrexin SCHEMBL29376907 | 0.99 | DHFR (0.79) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| Talotrexin SCHEMBL31476904 | 0.99 | DHFR (0.79) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| Talotrexin SCHEMBL1060264 | 0.99 | DHFR (0.79) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| Talotrexin SCHEMBL30947427 | 0.99 | DHFR (0.79) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| SCHEMBL14417307 | 0.92 | DHFR (0.70) | DHFR | |
| SCHEMBL24193104 | 0.91 | DHFR (0.69) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| SCHEMBL29027533 | 0.91 | DHFR (0.69) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| SCHEMBL30311295 | 0.91 | DHFR (0.69) | DHFRKDM4EMEN1ALDH1A1TYMS | |
| SCHEMBL29027575 | 0.91 | DHFR (0.69) | DHFRKDM4EMEN1ALDH1A1TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130855-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2026-05-14 | — | — | US | claimed |
| US-20250319123-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2025-10-16 | — | — | US | claimed |
| US-20250319188-A1 | ALPHA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2025-10-16 | — | — | US | claimed |
| US-20250161455-A1 | ALPHA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC | 2025-05-22 | — | — | US | claimed |
| US-20250082575-A1 | GAMMA POLYGLUTAMATED PRALATREXATE AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC | 2025-03-13 | — | — | US | claimed |
| US-12220431-B2 | Gamma polyglutamated antifolates and uses thereof | L.E.A.F. HOLDINGS GROUP LLC (US) | 2025-02-11 | — | — | US | claimed |
| US-12076402-B2 | Alpha polyglutamated antifolates and uses thereof | L.E.A.F. HOLDINGS GROUP LLC (US) | 2024-09-03 | — | — | US | claimed |
| US-12048767-B2 | Gamma polyglutamated pralatrexate and uses thereof | L.E.A.F. HOLDINGS GROUP LLC (US) | 2024-07-30 | — | — | US | claimed |
| US-20240251654-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2024-07-25 | — | — | US | claimed |
| US-20260130855-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2026-05-14 | — | — | US | disclosed |
| WO-2026085795-A1 | SILENCED FC REGIONS | PROTEINTECH GROUP, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260053806-A1 | GAMMA POLYGLUTAMATED METHOTREXATE AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260056209-A1 | ANTI-CCR8 ANTIBODIES AND USES THEREOF | GILEAD SCIENCES INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260048054-A1 | ALPHA POLYGLUTAMATED TETRAHYDROFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2026-02-19 | — | — | US | disclosed |
| US-11369588-B2 | NADPH production by the 10-formyl-THF pathway, and its use in the diagnosis and treatment of disease | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2022-06-28 | — | — | US | disclosed |
| US-11365430-B2 | Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system | CELLECTIS (FR) | 2022-06-21 | — | — | US | disclosed |
| EP-4010031-A1 | PROCESSES OF PREPARING POLYGLUTAMATED ANTIFOLATES AND USES OF THEIR COMPOSITIONS | L.E.A.F Holdings Group LLC (US) | 2022-06-15 | — | — | EP | disclosed |
| CN-114555127-A | Method for preparing polyglutamated antifolates and use of compositions thereof | L.E.A.F.控股集团公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-114246953-A | anti-cMet antibody drug conjugates and methods of use thereof | 艾伯维生物制药股份有限公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-114177308-A | anti-cMet antibody drug conjugates and methods of use thereof | 艾伯维生物制药股份有限公司 | 2022-03-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12048767-B2 | Gamma polyglutamated pralatrexate and uses thereof | IFNG, GMFG, IL2 | DHFR 30/4885KDM4E 2123/4885MEN1 3554/4885 |
| US-12220431-B2 | Gamma polyglutamated antifolates and uses thereof | GGCT, IFNG, FPGS | DHFR 14/4885KDM4E 2904/4885MEN1 3068/4885 |
| US-20250319123-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | GGCT, IFNG, FPGS | DHFR 14/4885KDM4E 2904/4885MEN1 3068/4885 |
| US-20260056209-A1 | ANTI-CCR8 ANTIBODIES AND USES THEREOF | CCR8, CCR3, CCR1 | DHFR 1329/4885KDM4E 3338/4885MEN1 4450/4885 |
| US-20250082575-A1 | GAMMA POLYGLUTAMATED PRALATREXATE AND USES THEREOF | IFNG, GMFG, IL2 | DHFR 30/4885KDM4E 2123/4885MEN1 3554/4885 |
| US-11369588-B2 | NADPH production by the 10-formyl-THF pathway, and its use in the diagnosis and treatment of disease | MTHFD1, DPYD, MTHFD2 | DHFR 4/4885KDM4E 2103/4885MEN1 2036/4885 |
| US-20250161455-A1 | ALPHA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | FPGS, GGCT, FOLR1 | DHFR 6/4885KDM4E 2822/4885MEN1 2370/4885 |
| US-20240251654-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | LEF1, EFNA1, EML4 | DHFR 2630/4885KDM4E 2782/4885MEN1 1476/4885 |
| US-20260048054-A1 | ALPHA POLYGLUTAMATED TETRAHYDROFOLATES AND USES THEREOF | FOLR2, FOLR1, FPGS | DHFR 5/4885KDM4E 806/4885MEN1 2360/4885 |
| US-12076402-B2 | Alpha polyglutamated antifolates and uses thereof | FPGS, GGCT, FOLR1 | DHFR 6/4885KDM4E 2822/4885MEN1 2370/4885 |
| US-20250319188-A1 | ALPHA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | FPGS, GGCT, FOLR1 | DHFR 6/4885KDM4E 2822/4885MEN1 2370/4885 |
| US-20260053806-A1 | GAMMA POLYGLUTAMATED METHOTREXATE AND USES THEREOF | FPGS, PDF, STOML2 | DHFR 159/4885KDM4E 2493/4885MEN1 2273/4885 |
| US-20260130855-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | FOLR2, FPGS, FOLR1 | DHFR 41/4885KDM4E 823/4885MEN1 3109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.